PMID- 14528059
OWN - NLM
STAT- MEDLINE
DCOM- 20040210
LR  - 20171101
IS  - 1422-2868 (Print)
IS  - 1422-2868 (Linking)
VI  - 16
IP  - 6
DP  - 2003 Nov-Dec
TI  - Testosterone metabolism in human skin cells in vitro and its interaction with 
      estradiol and dutasteride.
PG  - 356-66
AB  - Since the limited knowledge of cutaneous drug metabolism can impair the 
      development of specifically acting topical dermatics and transdermal application 
      systems, the cell-type-specific androgen metabolism in human skin and its 
      inhibition by drugs were investigated. Cultured human foreskin and scalp skin 
      keratinocytes and fibroblasts as well as occipital scalp dermal papilla cells 
      (DPC) were incubated with testosterone 10(-6) and 10(-8)M alone and in the 
      presence of 17alpha-estradiol, 17beta-estradiol or dutasteride for 24 h. 
      Androgens extracted from culture supernatants were subjected to thin-layer 
      chromatography and quantified by beta-counting. In keratinocytes and DPC, 
      dihydrotestosterone (DHT) was only formed to a low extent while androstenedione 
      was the main metabolite. In fibroblasts, DHT formation was pronounced following 
      10(-8)M testosterone. Dutasteride 10(-8)M completely suppressed 5alpha-dihydro 
      metabolite formation. 17alpha-Estradiol and 17beta-estradiol at nontoxic 
      concentrations decreased 17-ketometabolites. Human skin regulates testosterone 
      action by cell-type-specific activation or deactivation. Effects of 
      17alpha-estradiol in androgenetic alopecia are not due to 5alpha-reductase 
      inhibition. Dutasteride may be useful in acne and androgenetic alopecia.
CI  - Copyright 2003 S. Karger AG, Basel
FAU - Munster, U
AU  - Munster U
AD  - Abteilung fur Pharmakologie und Toxikologie, Institut fur Pharmazie, Freie 
      Universitat Berlin, Berlin, Deutschland.
FAU - Hammer, S
AU  - Hammer S
FAU - Blume-Peytavi, U
AU  - Blume-Peytavi U
FAU - Schafer-Korting, M
AU  - Schafer-Korting M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Skin Pharmacol Appl Skin Physiol
JT  - Skin pharmacology and applied skin physiology
JID - 9807277
RN  - 0 (Androgen Antagonists)
RN  - 0 (Azasteroids)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 3XMK78S47O (Testosterone)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase)
RN  - O0J6XJN02I (Dutasteride)
SB  - IM
MH  - 3-Oxo-5-alpha-Steroid 4-Dehydrogenase/biosynthesis
MH  - Androgen Antagonists/*pharmacology
MH  - Azasteroids/*pharmacology
MH  - Binding, Competitive/drug effects
MH  - Cell Survival/drug effects
MH  - Chromatography, Thin Layer
MH  - Dihydrotestosterone/pharmacology
MH  - Dutasteride
MH  - Estradiol/*pharmacology
MH  - Fibroblasts/drug effects/metabolism
MH  - Humans
MH  - Keratinocytes/drug effects/metabolism
MH  - Male
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Skin/cytology/enzymology/*metabolism
MH  - Testosterone/*metabolism
EDAT- 2003/10/07 05:00
MHDA- 2004/02/11 05:00
CRDT- 2003/10/07 05:00
PHST- 2002/07/26 00:00 [received]
PHST- 2003/10/07 05:00 [pubmed]
PHST- 2004/02/11 05:00 [medline]
PHST- 2003/10/07 05:00 [entrez]
AID - 72930 [pii]
AID - 10.1159/000072930 [doi]
PST - ppublish
SO  - Skin Pharmacol Appl Skin Physiol. 2003 Nov-Dec;16(6):356-66. doi: 
      10.1159/000072930.